Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 790

1.

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib.

Nyga R, Simon L, Chouaki T, Delette C, Bennis Y, Joseph C, Marolleau JP, Slama M, Zogheib E, Maizel J.

Crit Care. 2019 Mar 12;23(1):88. doi: 10.1186/s13054-019-2385-x. No abstract available.

2.

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.

Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.

Mol Cancer Res. 2019 Mar 12. pii: molcanres.0256.2018. doi: 10.1158/1541-7786.MCR-18-0256. [Epub ahead of print]

PMID:
30862686
3.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Harrington BK, Wheeler E, Hornbuckle K, Y Shana'ah A, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L.

Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231. [Epub ahead of print]

PMID:
30821551
4.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
5.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA; European Conference on Infections in Leukemia (ECIL).

Leukemia. 2019 Jan 30. doi: 10.1038/s41375-019-0388-x. [Epub ahead of print] Review.

PMID:
30700842
6.

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C.

Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28.

PMID:
30692684
7.

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):e184. No abstract available.

PMID:
30681658
8.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
9.

Acalabrutinib for adults with mantle cell lymphoma.

Jurczak W, Długosz-Danecka M, Wang M.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):179-187. doi: 10.1080/17512433.2019.1568868. Epub 2019 Jan 26. Review.

PMID:
30638402
10.

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.

Tobinai K, Uchida T, Fukuhara N, Nishikawa T.

Int J Hematol. 2019 Mar;109(3):366-368. doi: 10.1007/s12185-018-02577-8. Epub 2019 Jan 8. No abstract available.

PMID:
30623356
11.

Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening.

Guo C, Chang Y, Wang X, Zhang C, Hao P, Ding K, Li Z.

Chem Commun (Camb). 2019 Jan 15;55(6):834-837. doi: 10.1039/c8cc08685k.

PMID:
30574960
12.

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.

Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.

PMID:
30567753
13.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
14.

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS.

Blood. 2019 Feb 28;133(9):952-961. doi: 10.1182/blood-2018-07-862953. Epub 2018 Dec 13.

PMID:
30545835
15.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

PMID:
30501481
16.
17.

Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.

Yasu T, Momo K, Yasui H, Kuroda S.

Biomed Chromatogr. 2019 Mar;33(3):e4435. doi: 10.1002/bmc.4435. Epub 2018 Dec 11.

PMID:
30421802
18.

Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder.

Walliser C, Wist M, Hermkes E, Zhou Y, Schade A, Haas J, Deinzer J, Désiré L, Li SSC, Stilgenbauer S, Milner JD, Gierschik P.

Oncotarget. 2018 Sep 28;9(76):34357-34378. doi: 10.18632/oncotarget.26173. eCollection 2018 Sep 28.

19.

Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.

Li R, Du Y, Shen J.

SAR QSAR Environ Res. 2018 Nov;29(11):847-873. doi: 10.1080/1062936X.2018.1518927. Epub 2018 Oct 3.

PMID:
30280589
20.

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V.

Blood. 2018 Nov 22;132(21):2249-2259. doi: 10.1182/blood-2018-06-860593. Epub 2018 Sep 25.

PMID:
30254130

Supplemental Content

Loading ...
Support Center